secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2026-08-06T11:45:16+00:00
Accession:  0001193125-26-336772
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia reports positive Phase 3 HAELO data for lonvo-z; BLA submission expected H2 2026
--------------------------------------------------------------------------------

- Phase 3 HAELO trial met primary endpoint: lonvo-z reduced HAE attacks by 87% vs placebo (p<0.0001); mean monthly attack rate 0.26 vs 2.10.
- 62% of lonvo-z patients attack-free and therapy-free for 6-month efficacy period vs 11% placebo; all key secondary endpoints met (p<0.0001).
- Cash, cash equivalents and marketable securities $628.4M as of June 30, 2026, after $195M public offering; funds operations at least into 2028.
- Net loss $106.6M in Q2 2026 vs $101.3M in Q2 2025; R&D expenses $82.6M, G&A expenses $37.8M due to commercial buildout.
- Enrollment reinitiated in nex-z Phase 3 trials; genomic analysis identified HLA allele linked to liver transaminase elevations; HLA genotyping to be provided.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312526336772/0001193125-26-336772-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312526336772/ntla-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-336772

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer